诱导化疗联合同期放化疗对比单纯同期放化疗治疗局部晚期鼻咽癌:III期多中心随机对照试验长期结果
该III期随机试验比较诱导化疗(顺铂+氟尿嘧啶)联合同期放化疗与单纯同期放化疗在局部晚期鼻咽癌中的疗效。中位随访82.6个月后,联合组5年无病生存率、无远处转移生存率和总生存率均显著优于单纯组,且单纯组眼损伤比例更高。诱导化疗联合同期放化疗可推荐用于局部晚期鼻咽癌。
要点
- 诱导化疗联合同期放化疗较单纯同期放化疗显著改善5年无病生存率(73.4% vs 63.1%,P=0.007)。
- 联合组5年无远处转移生存率(82.8% vs 73.1%,P=0.014)和总生存率(80.8% vs 76.8%,P=0.040)均显著提高。
- 单纯同期放化疗组眼损伤发生率显著更高(16.4% vs 9.7%,P=0.029)。
核心结论
- 在局部晚期鼻咽癌患者中,诱导化疗联合同期放化疗较单纯同期放化疗提供长期的無病生存、无远处转移生存和总生存获益。
研究设计与样本
- 随机、开放标签、III期多中心试验,比较诱导化疗联合同期放化疗与单纯同期放化疗。
- 纳入III-IVB期(除外T3N0-1)鼻咽癌患者,意向性治疗人群共476例随机分组。
- 诱导化疗方案为顺铂80 mg/m2 d1联合氟尿嘧啶800 mg/m2 d1-5,每3周重复,共2周期,随后行同期放化疗。
- 两组同期放化疗均采用顺铂80 mg/m2每3周一次。
- 主要终点为无病生存期和无远处转移生存期。
主要发现
- 中位随访82.6个月,联合组5年无病生存率为73.4%(95%CI 67.7-79.1),单纯组为63.1%(95%CI 56.8-69.4),P=0.007。
- 联合组5年无远处转移生存率为82.8%(95%CI 77.9-87.7),单纯组为73.1%(95%CI 67.2-79.0),P=0.014。
- 联合组5年总生存率为80.8%,单纯组为76.8%,P=0.040。
- 单纯同期放化疗组眼损伤比例显著高于联合组(16.4% [39/238] vs 9.7% [23/238],P=0.029)。
关键数值与推荐
- 5年无病生存率:联合组73.4%(95%CI 67.7-79.1) vs 单纯组63.1%(95%CI 56.8-69.4),P=0.007。
- 5年无远处转移生存率:联合组82.8%(95%CI 77.9-87.7) vs 单纯组73.1%(95%CI 67.2-79.0),P=0.014。
- 5年总生存率:联合组80.8% vs 单纯组76.8%,P=0.040。
- 眼损伤发生率:单纯组16.4%(39/238) vs 联合组9.7%(23/238),P=0.029。
临床怎么用
- 对于III-IVB期(除外T3N0-1)局部晚期鼻咽癌患者,可考虑采用诱导化疗(顺铂+氟尿嘧啶)联合同期放化疗方案。
- 该方案具有长期生存获益,且眼损伤发生率低于单纯同期放化疗。
局限性
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Initial 3-year results from our clinical trial in locoregionally advanced nasopharyngeal carcinoma (NPC) patients showed that induction chemotherapy (IC) with cisplatin and fluorouracil resulted in improved disease-free survival (DFS) with a marginally significant effect on distant metastasis-free survival (DMFS), but the effect of IC on locoregional relapse-free survival and overall survival (OS) did not differ significantly. Here, we present 5-year follow-up results. PATIENTS AND METHODS: Our trial was a randomised, open-label phase III trial comparing IC followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone in patients with stage III-IVB (except T3N0-1) NPC. The IC followed by CCRT group received cisplatin (80 mg/m2 d1) and fluorouracil (800 mg/m2 d1-5) every 3 weeks for two cycles before CCRT. Both groups were treated with 80 mg/m2 cisplatin every 3 weeks concurrently with radiotherapy. The primary end-points were DFS and DMFS. We did efficacy analyses in the 476 randomised patients (intention-to-treat population). RESULTS: After a median follow-up of 82.6 months, the 5-year DFS rate was 73.4% (95% confidence interval [CI] 67.7-79.1) in the IC followed by CCRT group and 63.1% (95% CI 56.8-69.4) in the CCRT alone group (p = 0.007). The 5-year DMFS rate was also significantly higher in the IC followed by CCRT group (82.8%, 95% CI 77.9-87.7) than in the CCRT alone group (73.1%, 95% CI 67.2-79.0, p = 0.014). Our updated analysis revealed an OS benefit of IC: the 5-year OS rate was 80.8% in the IC followed by CCRT group versus 76.8% in the CCRT alone group (p = 0.040). The proportion of patients with eye damage was significantly higher in the CCRT alone group than the IC followed by CCRT group (16.4% [39/238] versus 9.7% [23/238], p = 0.029). CONCLUSION: IC followed by CCRT provides long-term DFS, DMFS and OS benefits compared with CCRT alone in locoregionally advanced NPC and, therefore, can be recommended for these patients.
引用
- Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019. PMID: 31425966. doi:10.1016/j.ejca.2019.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。